

## Editor

Tore K Kvien

## Associate Editors

Francis Berenbaum  
Hans Bijlsma  
David Pisetsky  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Iain McInnes

## Editorial office

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 7383 6250  
F: +44 (0)20 7383 6668  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)  
Impact Factor: 9.270

**Disclaimer:** ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

**Copyright:** © 2015 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Teichet and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431  
POSTMASTER: send address changes to Annals of the Rheumatic Diseases, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.  
Register using this QR code.

### Editorial

- 321** Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation?  
*S L Kristensen, I B McInnes, N Sattar*

### Viewpoint

- 323** Statistical review: frequently given comments  
*S Lydersen*

### Clinical and epidemiological research

- 326** Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study  
*A Ogdén, Y D Yu, K Haynes, T J Love, S Malhi, Y Jiang, A B Troxel, S Hennessy, S E Kimmel, D J Margolis, H Choi, N N Mehta, J M Gelfand*

**333** Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate  
*E C Keystone, P C Taylor, E Drescher, D E Schlichting, S D Beattie, P-Y Berclaz, C H Lee, R K Fidelus-Gort, M E Luchi, T P Rooney, W L Macias, M C Genovese*

- 341** Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study  
*K V C Wevers-de Boer, L Heimans, K Visser, J Kälvesten, R J Goekoop, M van Oosterhout, J B Harbers, C Bijkerke, M Steup-Beekman, M P D M de Buck, P B J de Sonnaville, T W J Huizinga, C F Allaart*

- 347** Worsening of pain and function over 5 years in individuals with 'early' OA is related to structural damage: data from the Osteoarthritis Initiative and CHECK (Cohort Hip & Cohort Knee) study  
*J Wesseling, S M A Bierma-Zeinstra, M Kloppenburg, R Meijer, J W J Bijlsma*

- 354** Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab  
*M Neovius, E V Arkema, H Olsson, J K Eriksson, L E Kristensen, J F Simard, J Askeling, for the ARTIS Study Group*

- 361** Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects  
*C L M Krieckaert, S C Nair, M T Nurmohamed, C J J van Dongen, W F Lems, F P J G Lafèbre, J W J Bijlsma, H Koffijberg, G Wolbink, P M J Welsing*

- 369** Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan  
*C-F Kuo, M J Grainge, L-C See, K-H Yu, S-F Luo, A M Valdes, W Zhang, M Doherty*

- 375** Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins  
*A H Hensvold, P K E Magnusson, V Joshua, M Hansson, L Israelsson, R Ferreira, P J Jakobsson, R Holmdahl, L Hammarström, V Malmström, J Askeling, L Klareskog, A I Catrina*

- 381** Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000–2010  
*A-B Aga, E Lie, T Uhlig, I C Olsen, A Wierød, S Kalstad, E Rødevand, K Mikkelsen, T K Kvien, E A Haavardsholm*

- 389** Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study  
*Y Tanaka, S Hirata, S Kubo, S Fukuyo, K Hanami, N Sawamukai, K Nakano, S Nakayamada, K Yamaoka, F Sawamura, K Saito*

- 396** Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up  
*E L Kneepkens, J C-C Wei, M T Nurmohamed, K-J Yeo, C Y Chen, I E van der Horst-Bruinsma, D van der Kleij, T Rispen, G Wolbink, C L M Krieckaert*

- 402** Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients  
*M B Calasan, E den Boer, M C F J de Rotte, S J Vastert, S Kamphuis, R de Jonge, N M Wulffraat*

- 408** Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis  
*M C F J de Rotte, E den Boer, P H P de Jong, S M F Pluijm, M B Calasan, A E Weel, A M Huisman, A H Gerards, B van Schaeybroeck, N M Wulffraat, J Lindemans, J M W Hazes, R de Jonge*

- 415** Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF $\alpha$  inhibitors and rituximab  
*J Listing, J Keew, B Manger, G-R Burmester, D Pattloch, A Zink, A Strangfeld*

- 422** Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss  
*J-P Pelletier, C Roubille, J-P Raynaud, F Abram, M Dorais, P Delorme, J Martel-Pelletier*

### MORE CONTENTS ►



This article has been chosen by the Editor to be of special interest or importance and is freely available online.




This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



- 430** The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor  
 OPEN ACCESS  
*L R Harold, G W Reed, J M Kremer, J R Curtis, D H Solomon, M C Hochberg, J D Greenberg*

- 437** Quantitative syndesmophyte measurement in ankylosing spondylitis using CT: longitudinal validity and sensitivity to change over 2 years  
*S Tan, J Yao, J A Flynn, L Yao, M M Ward*

---

### Basic and translational research

- 444** Anti-inflammatory effects of cell-based therapy with tyrosine hydroxylase-positive catecholaminergic cells in experimental arthritis  
*Z Jenei-Lanzl, S Capellino, F Kees, M Fleck, T Lowin, R H Straub*

- 452** Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming  
*K V Rupanagudi, O P Kulkarni, J Lichtnekert, M N Darisipudi, S R Mulay, B Schott, S Gruner, W Haap, G Hartmann, H-J Anders*

- 464** TNF $\alpha$  regulates cortisol metabolism in vivo in patients with inflammatory arthritis  
*D E Nanus, A D Filer, B Hughes, B A Fisher, P C Taylor, P M Stewart, C D Buckley, I McInnes, M S Cooper, K Raza*

---

### Letters

- 470** Cytokine profiling at disease onset: support for classification of young antinuclear antibody-positive patients as a separate category of juvenile idiopathic arthritis  
*T van den Broek, E Hoppenreijs, J Meering, R Scholman, H G Otten, J F Swart, A Marini, B Prakken, W de Jager*

- 472** The effect of mindfulness-based stress reduction on disease activity in people with rheumatoid arthritis: a randomised controlled trial  
*F A Fogarty, R J Booth, G D Gamble, N Dalbeth, N S Consedine*

- 474** Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs  
*E H Vogelzang, M F Pouw, M Nurmohamed, E L Kneepkens, T Rispens, G J Wolbink, C L M Krieckaert*

- 475** The EULAR Outcome Measures Library: an evolutionary database of validated patient-reported instruments  
*I Castrejón, L Gossec, L Carmona*

---

### Correction

- 476** Correction

---

### Electronic page

- e11** Thank you to our reviewers 2014